- €1.89bn
- €2.83bn
- €1.16bn
Dermapharm rises on H1 beat
Brief: Dermapharm H1 Adjusted Group EBITDA Margin At 28.9%
Brief: Dermapharm H1 Adjusted EBITDA EUR 168 Million
Brief: Dermapharm Invests In Family-Owned Austrian Pharmaceutical Company Montavit
Dermapharm tops German small-caps on Q1 beat
Brief: Dermapharm Confirms 2023 Outlook
Brief: Dermapharm Q1 Adj. EBITDA Margin at 33.2%
Brief: Dermapharm Holding Sees Adjusted Consolidated EBITDA Between EUR 300 And 310 Mln In 2023
Brief: Dermapharm Proposes Dividend Of EUR 1.05 Per Share For 2022
Brief: Dermapharm Holding: Revenue To Exceed One Billion In 2023
Brief: Dermapharm Posts FY Revenue in Line with Expectations
Brief: Dermapharm Buys Arkopharma
Dermapharm Holding rises after 'solid' 9-month results
Brief: Dermapharm Holding: 9-Month Consolidated Revenue Up At EUR 734.3 Mln
Europe Research Roundup: Almirall, Ipsen, Unilever
Brief: Dermapharm H1 EBITDA At EUR 148.7 Mln, Up 8.5% Y/Y
Europe Research Roundup: Gresham House, Sixt SE and Synthomer
Brief: Dermapharm H1 Adjusted Group EBITDA Up 9% At EUR 149 Mln
German stocks - Factors to watch on August 23